Helping The others Realize The Advantages Of Antidepressant agent 5
MI-CP151 was a section 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre analyze To guage multiple intravenous doses of sifalimumab, in adult people with dermatomyositis or polymyositis (NCT00533091). Primary trial aims had been to evaluate the protection and tolerability of sifalimumab in dermatomyositis or polymyositis